Chapmans Ltd. (ASX: CHP)
A $6M capped ASX Listed Investment Company that takes high conviction bets on emerging companies is now in advanced stage negotiations with a number of substantial high quality medical cannabis investment opportunities.
However, one opportunity in particular may be close to fruition as the company expects to close on a medical cannabis deal in North America any day now.
In preparation for its entry into the medical cannabis market, this company has already created a subsidiary to evaluate and invest in targeted segments of the medicinal cannabis sector including veterinary science and animal treatment.
The company is also set to pursue global licensing and distribution opportunities with an initial focus on North America – the world’s largest medicinal cannabis market – before looking at other regions.
CHP has invested in a number of businesses and is actively involved with and puts cash in companies or ventures that could potentially reap near-term rewards, in monetary or strategic terms.
CHP already contains four different brands, or separate businesses with entirely delineated operations across waste management and digital media. An investment in a medical cannabis company fits well into its diversified investment strategy, particularly as this is an industry expected to be worth $55.8 billion by 2025.
The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.
By taking key stakes in companies across potentially high-growth sectors, CHP is effectively sinking its fingers into several very different pies.
However, confirmation of a deal in the medical cannabis space may be enough for this stock’s valuation to quickly escalate.